Related Experiment Video

Updated: Mar 23, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K

Takotsubo cardiomyopathy after administration of norepinephrine

Khaled Sherif1, Sharmila Sehli1, Leigh A Jenkins1

  • 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.

Proceedings (Baylor University. Medical Center)
|April 2, 2016
PubMed

Insights

Stress-induced cardiomyopathy, a temporary heart dysfunction, may be caused by excess catecholamines. A case report details a patient developing this condition after a norepinephrine administration error.

Area of Science:

  • Cardiology
  • Pharmacology
  • Pathophysiology

Background:

  • Stress-induced cardiomyopathy (SICM) presents as transient cardiac dysfunction.
  • The exact pathophysiology of SICM remains unclear.
  • Catecholamine surge is a suspected cause of SICM.

Observation:

  • A patient developed SICM following norepinephrine administration.
  • Norepinephrine was administered due to a nursing error.
  • This case provides a unique clinical scenario to study SICM.

Findings:

  • The case suggests a direct link between exogenous norepinephrine and SICM.
  • This challenges the notion that SICM is solely due to endogenous catecholamine surge.
  • Further research is needed to elucidate the precise mechanisms.

Implications:

  • Understanding SICM pathophysiology is crucial for patient management.
  • This case highlights the potential iatrogenic risks of vasopressor administration.
  • Further studies may reveal novel therapeutic targets for SICM.

More Related Videos

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

21.1K
Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

18.9K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
312